Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL-NK RCC in Advanced Clear Cell Renal Cell Carcinoma
NCT07551349Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Apr 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EB-701/CA9-NK in clear cell renal cell carcinoma (ccRCC), sponsored by Biotech Pharmaceutical. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Recommended Phase 2 Dose at 8 weeks. Started Feb 2026; status: recruiting.
02
Drugs
EB-701/CA9-NK
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07551349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551349.